Shockwave Medical, Inc.

Stock Symbol: 
Case Status: 

Ademi LLP is investigating Shockwave (Nasdaq: SWAV) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson.

In the transaction, Shockwave stockholders will own only $335.00 per share in cash, corresponding to an enterprise value of approximately $13.1 billion including cash acquired. The transaction agreement unreasonably limits competing transactions for Shockwave by imposing a significant penalty if Shockwave accepts a competing bid. Shockwave insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Shockwave’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.